Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.52 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.52 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.52 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.52 |
| ▸ | PNLIP | P16233 | 4/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | PARG | Q86W56 | 1/20 | 0.46 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3137838 | 0.91 | KDM4E (0.53) | KDM4EMEN1NPC1MAPTPKM | |
| SCHEMBL8915931 | 0.90 | KDM4E (0.52) | KDM4EMEN1NPC1MAPTPKM | |
| SCHEMBL3140021 | 0.90 | KDM4E (0.49) | KDM4EMEN1NPC1MAPTPKM | |
| SCHEMBL3133310 | 0.87 | KDM4E (0.48) | KDM4EMEN1NPC1MAPTPKM | |
| SCHEMBL3142159 | 0.86 | KCNQ3 (0.67) | KDM4EMEN1NPC1MAPTPKM | |
| SCHEMBL3142227 | 0.86 | KDM4E (0.52) | KDM4EMEN1NPC1MAPTPKM | |
| SCHEMBL13742001 | 0.85 | KDM4E (0.67) | KDM4EMEN1NPC1MAPTPKM | |
| SCHEMBL3131474 | 0.85 | KDM4E (0.53) | KDM4EMEN1NPC1MAPTPKM | |
| SCHEMBL3146704 | 0.84 | KCNQ3 (0.52) | KDM4EMEN1NPC1MAPTPKM | |
| SCHEMBL11959943 | 0.83 | NPC1 (0.59) | KDM4EMEN1NPC1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | KDM4E 2010/4885MEN1 1851/4885NPC1 1397/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | KDM4E 988/4885MEN1 3512/4885NPC1 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.